icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2021
Back grey_arrow_rt.gif
 
 
 
Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301)
 
 
  AASLD 2021 Nov 12-15
 
Lena Allweiss, Annika Volmari, Yvonne Ladiges, Corinna Eggers, Katja Giersch, Katrin Schoneweis, Vithika Suri, Jeffrey Wallin, Heiner Wedemeyer, Stephan Urban, Marc Lütgehetmann, Jan-Hendrik Bockmann, Maura Dandri

1116211

1116212

1116213

1116214

1116215

1116216